MC1R raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-01 and is reviewed periodically as new material appears.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilised powder | Reconstitution is required before use in most assays |
| Solubility class | Freely soluble in water and acetonitrile; sparingly soluble in nonpolar solvents | Aqueous solutions may benefit from slight acidification |
| Typical storage temperature | -20 °C or lower, desiccated and protected from light | Short-term transport at 2-8 °C is common practice |
| Primary degradation routes | Oxidation, hydrolysis, aggregation | Tryptophan and histidine residues are the main oxidation targets |
| Quality marker | Chromatographic purity by peak area | Does not capture counter-ion content or residual solvents |
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
== Behavior == Nocturnal and arboreal, the Wagler's pit viper appears quite sluggish, as it remains motionless for long periods of time waiting for prey to pass by. When prey does pass by, or if disturbed, it can strike quickly.
=== Pharmacological inhibition === System Xc- can be inhibited by many small molecules. Excess amounts of the endogenous substrate glutamate inhibits the function of system Xc-. Synthetic small molecules such as erastin, sulfasalazine, and sorafenib can inhibit system Xc- function and induce ferroptosis.
In March 1866, a month after the fall, Eddy and her husband (then married for 13 years) moved into an unfurnished room in Lynn. At some point her husband left and Eddy was evicted, unable to pay the $1.50 weekly rent. He appears to have returned briefly—they moved to a boarding house in July, and in August he paid Dr. Cushing's bill from the fall—but the marriage was over. He sent her $200 a year for a time, and they divorced in 1873. Her first student was Hiram Crafts, a shoe worker in whose house she stayed, who advertised for patients himself in May 1867, offering a cure for "Consumption, Catarrh, Scrofula, Dyspepsia and Rheumatism." Eddy asked Crafts to set up a practice with her, but the plan came to nothing. In addition to teaching, Eddy had started to write; toward the end of 1866 she began work on an allegorical interpretation of Genesis, intended as the first volume of a book (never published), The Bible in its Spiritual Meaning. In the summer of 1868, while lodging with spiritualist Sarah Bagley in Amesbury, Eddy advertised for students in a Spiritualist magazine, the Banner of Light, as Mary B. Glover (her first husband's surname). The ad promised a "principle of science" that would heal with "[n]o medicine, electricity, physiology or hygiene required for unparalleled success in the most difficult cases". Sally Wentworth, another Spiritualist, offered Eddy $300-worth of bed and board in Stoughton if Eddy would treat her daughter's lung condition and teach Wentworth the healing method.
Sources: en.wikipedia.org
=== Ceasefire attempts === Syrian minister of defense Murhaf Abu Qasra announced a ceasefire effective from 15 July 2025 after an agreement with the Druze leaders in Suwayda. The Syrian Ministry of Interior warned against any damage to private or public property in Suwayda. According to the ceasefire agreement, it was not a complete withdrawal of the administration, and it would be able to continue to maintain police forces in the district, which would operate together with local Druze, but it was required, as stated, to withdraw the military forces it had sent there in the battles in recent days. A mechanism was also agreed upon to regulate the issue of possession of heavy weapons in the area. The agreement also stipulates the establishment of an investigative committee that will examine atrocities committed by militants and regime members against the Druze, according to reports. Following the second ceasefire announced on 16 July 2025, Syrian president Ahmed al-Sharaa addressed the nation stating that the government's priority is to protect Druze citizens as Israel continues its assaults on Syria. He further said "we reject any attempt to drag you into hands of an external party. We are not among those who fear the war. We have spent our lives facing challenges and defending our people, but we have put the interests of the Syrians before chaos and destruction".
=== Belgium === In Belgium, a clinical biologist (biologiste clinique) is a medical doctor or pharmacist who has completed a five-year postgraduate specialization in clinical biology (biologie clinique). This specialization is regulated by the Belgian Ministry of Public Health, and clinical biologists work in both hospital and private laboratories. Their training includes rotations in different laboratory disciplines, including hematology, microbiology, and clinical chemistry. They are responsible for interpreting laboratory results, ensuring quality control, and advising clinicians on diagnostic strategies.
=== Journals === ACS Chemical Biology – The new Chemical Biology journal from the American Chemical Society. Bioorganic & Medicinal Chemistry – The Tetrahedron Journal for Research at the Interface of Chemistry and Biology ChemBioChem – A European Journal of Chemical Biology Chemical Biology – A point of access to chemical biology news and research from across RSC Publishing Cell Chemical Biology – An interdisciplinary journal that publishes papers of exceptional interest in all areas at the interface between chemistry and biology. chembiol.com Journal of Chemical Biology – A new journal publishing novel work and reviews at the interface between biology and the physical sciences, published by Springer. link Journal of the Royal Society Interface – A cross-disciplinary publication promoting research at the interface between the physical and life sciences Molecular BioSystems – Chemical biology journal with a particular focus on the interface between chemistry and the -omic sciences and systems biology. Nature Chemical Biology – A monthly multidisciplinary journal providing an international forum for the timely publication of significant new research at the interface between chemistry and biology. Wiley Encyclopedia of Chemical Biology link
As mentioned before, microneedles have also been explored for local targeted drug delivery at other drug delivery sites, such as the gastrointestinal, ocular, vascular etc., of which, ocular, vaginal and gastrointestinal have shown increasingnly convincing outcomes where they serve as a more efficient, localised drug delivery system, without the drawbacks of systemic exposure/toxicity. The major goal of any microneedle design is to penetrate the skin's outermost layer, the stratum corneum (10-15μm). Microneedles are long enough to cross the stratum corneum but not so long that they stimulate nerves which are located deeper in the tissues and therefore cause little to no pain. Research has shown that there is a limit on the type of drugs that can be delivered through intact skin. Only compounds with a relatively low molecular weight, like the common allergen nickel (130 Da), can penetrate the skin. Compounds that weigh more than 500 Da cannot penetrate the skin.
Sources: en.wikipedia.org
Solutions are best kept cold, protected from light, and buffered to a pH that limits hydrolysis. Dividing a stock into single-use aliquots avoids repeated freeze-thaw cycles, which measurably reduce the intact parent peak over time.
Reversed-phase chromatography establishes a purity profile, while electrospray or matrix-assisted laser desorption mass spectrometry confirms that the observed mass matches the expected sequence. Together they support, but do not fully prove, identity and purity.
Reviews generally characterise it as thin, dominated by small and often uncontrolled studies. Several authors explicitly note that findings on pigmentation, appetite and sexual function have not been confirmed in adequately powered controlled trials.
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.